Related Experiment Video

Updated: Aug 19, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

The impact of antidiabetic therapies on cardiovascular disease

Brandy Panunti1, Biju Kunhiraman, Vivian Fonseca

  • 1Department of Medicine, Section of Endocrinology, Tulane University Medical Center, New Orleans, LA 70112-2699, USA.

Current Atherosclerosis Reports
|February 3, 2005
PubMed

Insights

People with diabetes face high cardiovascular disease risks. Certain diabetes medications, like metformin, may reduce these risks independently of blood sugar control, unlike other treatments.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a major cause of mortality in diabetic patients.
  • Glycemic control's impact on cardiovascular events remains inconclusive.
  • Different glucose-lowering agents possess varying cardiovascular risk profiles.

Purpose of the Study:

  • To review the effects of various glucose-lowering therapies on cardiovascular risk factors and outcomes in patients with diabetes.
  • To highlight medications with proven cardiovascular benefits.

Main Methods:

  • Literature review of studies examining the cardiovascular effects of antidiabetic medications.
  • Analysis of clinical trial data and epidemiological studies.

Main Results:

  • Metformin is the only oral agent demonstrated to reduce cardiovascular events independently of glycemic control.
  • Insulin sensitizers (e.g., thiazolidinediones) improve insulin resistance and may mitigate CVD risk factors.
  • Insulin therapy shows acute benefits in critically ill patients and those with coronary artery disease, but long-term effects are uncertain.
  • Insulin secretagogues have minimal impact on cardiovascular risk factors and outcomes.

Conclusions:

  • The choice of glucose-lowering therapy significantly influences cardiovascular outcomes in patients with diabetes.
  • Metformin and insulin sensitizers show promise in managing cardiovascular risk in this population.
  • Further research is needed to clarify the long-term cardiovascular effects of insulin therapy.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...